DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hemiconvulsion hemiplegia epilepsy syndrome", "One side convulsions", "Hemiplegia", "Epilepsy syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 4cc of lidocaïne®; 9060X; BOTOX; BOTULINUM TOXIN TYPE A; Baclofen; Balance; Botox; Botulinum toxin; Botulinum toxin A; Botulinum toxin type A; Brivaracetam; Diagnostic Test: Nociceptor flexor reflex; Diagnostic Test: gait analysis; Edonerpic; Gradient; HC-58; Lacosamide; MEOPA; Medicinal air; Melatonin; Other: Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.; Other: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire; Oxybate; Padsevonil; Placebo; Procedure: upper limb muscle block; SPM927; Sodium Oxybate; Sodium oxybate; T-817MA; Time delay treatment of botulinum toxin; Triheptanoin; Ucb 34714

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01623622 (ClinicalTrials.gov)	July 2012	18/6/2012	Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke	A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke	Severe Upper Limb Hemiplegia	Drug: HC-58;Drug: Placebo	Asahi Kasei Pharma Corporation	NULL	Completed	20 Years	N/A	All	270	Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01623622
(ClinicalTrials.gov)

July 2012

18/6/2012

Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke

A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke

Severe Upper Limb Hemiplegia

Drug: HC-58;Drug: Placebo

Asahi Kasei Pharma Corporation

NULL

Completed

20 Years

N/A

All

270

Phase 2

Japan